Informace o publikaci

European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma

Autoři	ENGELHARDT Monika UDI Josefina KLEBER Martina SPENCER Andrew ROCCI Alberto KNOP Stefan BRUNO Benedetto BRINGHEN Sara PÉREZ-SIMÓN José A ZWEEGMAN Sonja DRIESSEN Christoph PATRIARCA Francesca GRAMATZKI Martin TERPOS Evangelos SEZER Orhan KROPFF Martin STRAKA Christian JOHNSEN Hans E WAAGE Anders BOEGSTED Martin LOKHORST Henk HÁJEK Roman MORGAN Gareth BOCCADORO Mario LUDWIG Heinz CAVO Michele POLLIACK Aaron SONNEVELD Pieter EINSELE Hermann PALUMBO Antonio
Rok publikování	2010
Druh	Článek v odborném periodiku
Časopis / Zdroj	Leukemia & lymphoma
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.3109/10428194.2010.516378
Obor	Onkologie a hematologie
Klíčová slova	Multiple myeloma (MM); European Myeloma Network Trialist Group (EMN-TG); novel agents; current diagnostic; therapeutic; research endeavors
Popis	Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice.